Prof. Timo Minssen

Joint project between Hanken (Dep of Accounting and Commercial law), the Aalto University (Department of Engineering Design and Production) and the University of Helsinki (School of law) ), conducted in co-operation with the IPR University Centre and the Universities of Copenhagen, Bournemouth, and Pforzheim.

This research project is an international collaborative study that strives for groundbreaking results on fundamental questions related to intellectual property (IP) law, rising… Vis mere

Joint project between Hanken (Dep of Accounting and Commercial law), the Aalto University (Department of Engineering Design and Production) and the University of Helsinki (School of law) ), conducted in co-operation with the IPR University Centre and the Universities of Copenhagen, Bournemouth, and Pforzheim.

This research project is an international collaborative study that strives for groundbreaking results on fundamental questions related to intellectual property (IP) law, rising technologies (such as additive manufacturing), innovation, and policies. The AdManI project will run during 2015-2016 and will be financed by Tekes.

Vis mindre

Once again I will be the course director of the 3rd edition of the “Copenhagen Summer School” for pharma professionals. The course will be held from August 18th -22nd at the Frederiksberg campus of the University of Copenhagen. It covers the hottest regulatory and scientific topics in the field from a comparative US/European viewpoint including a special day focusing on emerging markets in Asia. I will teach a variety of lectures with case studies and will be joined by a team of expert… Vis mere

Once again I will be the course director of the 3rd edition of the “Copenhagen Summer School” for pharma professionals. The course will be held from August 18th -22nd at the Frederiksberg campus of the University of Copenhagen. It covers the hottest regulatory and scientific topics in the field from a comparative US/European viewpoint including a special day focusing on emerging markets in Asia. I will teach a variety of lectures with case studies and will be joined by a team of expert colleagues from medicine authorities, IP Law firms, major pharmaceutical companies, researchers, and the former White House Director of international IP. Vis mindre

coPI, WP leader and member of the steering committee, 1 PhD student and 1 PostDoc

coPI, WP leader and member of the steering committee, 1 PostDoc

Principal Investigator, WP leader & MOSC

Counterfeiting medicines have become an enormous industry. Although counterfeit medicines may look genuine, there are often no or very little active ingredient in them. Furthermore, they are often produced under conditions unsuitable for manufacturing medicines and without respect for intellectual property rights and human life.

The problem is well-known in countries with weak quality assurance systems where stories of counterfeit medicines reaching patients in large numbers are routine.… Vis mere

Counterfeiting medicines have become an enormous industry. Although counterfeit medicines may look genuine, there are often no or very little active ingredient in them. Furthermore, they are often produced under conditions unsuitable for manufacturing medicines and without respect for intellectual property rights and human life.

The problem is well-known in countries with weak quality assurance systems where stories of counterfeit medicines reaching patients in large numbers are routine. However, several high profile cases in Europe and the United States have made it apparent that also the Western countries need to react in order to protect their supply chains.

Through our research we study;

• the distribution of counterfeit medicines in countries without strong regulatory bodies

• how highly regulated supply chains attempt to block the distribution of counterfeit medicines

• the development and implementation of new EU legislation

• how private and public stakeholders work together to combat counterfeit medicines

The research on counterfeit medicines is done in collaboration with Centre for Information and Innovation Law at the Faculty of Law.
Vis mindre

DEVELOPMENT AND COORDINATION OF SYNTHETIC BIOLOGY IN THE EUROPEAN RESEARCH AREA

The ERASynBio Initiative

ERASynBio is an initiative of international funding agencies working together to promote the robust development of Synthetic Biology and to structure and coordinate national efforts and funding programs. The network was created in 2012 and funded as an ERA-Net by the European Commission under FP7 until 2014. From 2015 onwards, ERASynBio will operate as a self-sustainable… Vis mere

DEVELOPMENT AND COORDINATION OF SYNTHETIC BIOLOGY IN THE EUROPEAN RESEARCH AREA

The ERASynBio Initiative

ERASynBio is an initiative of international funding agencies working together to promote the robust development of Synthetic Biology and to structure and coordinate national efforts and funding programs. The network was created in 2012 and funded as an ERA-Net by the European Commission under FP7 until 2014. From 2015 onwards, ERASynBio will operate as a self-sustainable initiative (i.e. without the financial support of the EC), with most ERA-Net partners continuing their collaboration in the next years.

Along with the 2 joint calls, several supporting measures were initiated by ERASynBio in order to support the development of high quality Synthetic Biology research. One major effort was the development of a Strategic Vision accompanied by a series of targeted recommendations designed to empower national and international funding organizations, policy bodies and other stakeholders.

It is the aim of the ERASynBio initiative to further support joint activities that focus on transnational coordination, capacity building, sharing resources and facilities, and - last but not least - joint calls for proposals in the field of synthetic biology.

Coordinator

Dr. Marion Karrasch-Bott
Phone: +49 2461 61 6245
Mail: m.karrasch@fz-juelich.de
Vis mindre

The main objective of the ERANET proposal Systems Biology Applications - ERASysAPP (app = application = translational systems biology) is to promote multidimensional and complementary European systems biology projects, programmes and research initiatives on a number of selected research topics. Inter alia, ERASysAPP will initiate, execute and monitor a number of joint transnational calls on systems biology research projects with a particular focus on applications - or in other words so called… Vis mere

The main objective of the ERANET proposal Systems Biology Applications - ERASysAPP (app = application = translational systems biology) is to promote multidimensional and complementary European systems biology projects, programmes and research initiatives on a number of selected research topics. Inter alia, ERASysAPP will initiate, execute and monitor a number of joint transnational calls on systems biology research projects with a particular focus on applications - or in other words so called translational systems biology research approaches (application-oriented and/or industry-relevant). The joint call proposals and their respective attention will be on applied aspects of complex biological processes in microorganisms, plants and animals. As common feature, all addressed proposal topics will tackle biological and physiological processes of common interest in the field of life sciences and biotechnology.
In order to reach our ambitious goals, ERASysAPP has been outlined to initiate novel activities and impulses for SB in the ERA. Taking past successful developments and achievements into account, ERASysAPP will be able to continue and build on work, which has been performed by the previously funded successful ERANET on SB, ERASysBio and its spin-offs ERASysBio+, SysMo and SysMO2 (www.erasysbio.net). This is advantageous, since it allows for the efficient use of past experiences and tangible results of ERASysBio and will guarantee for maximum synergistic effects. Although building on the improvements of ERASysBio, ERASysAPP will provide a bundle of novel aspects, ideas, activities and sustainable new features to push SB towards new challenges and horizons. Apart from setting up joint transnational calls and giving impulses for industry to apply more SB approaches, ERASysAPP will focus on horizontal topics such as improved data management and sharing, training and networking with national, transnational, and EU SB initiatives as well as programmes outside the ERA Vis mindre

Gave presentation about regulation of approval of biosimilars and determination of interchangeability/substitution of biosimilars in Europe at Summer University program aimed at industry and scientific community participants by the University of Copenhagen.